Drug profile · INN
brincidofovir
TEMBEXA
brincidofovir (TEMBEXA) is a dna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — brincidofovir
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
brincidofovir (TEMBEXA) is a dna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA polymerase inhibitor
Primary target: DNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is brincidofovir?
brincidofovir (TEMBEXA) is a dna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for brincidofovir?
TEMBEXA is a marketed brand name for brincidofovir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brincidofovir?
brincidofovir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.